HRP20150037T4 - Farmaceutske formulacije koje sadrže metilnaltrekson - Google Patents
Farmaceutske formulacije koje sadrže metilnaltrekson Download PDFInfo
- Publication number
- HRP20150037T4 HRP20150037T4 HRP20150037TT HRP20150037T HRP20150037T4 HR P20150037 T4 HRP20150037 T4 HR P20150037T4 HR P20150037T T HRP20150037T T HR P20150037TT HR P20150037 T HRP20150037 T HR P20150037T HR P20150037 T4 HRP20150037 T4 HR P20150037T4
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical formulations
- formulations containing
- containing methylnaltrexone
- methylnaltrexone
- solution
- Prior art date
Links
- JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 title claims 2
- 229960002921 methylnaltrexone Drugs 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Claims (1)
1. Farmaceutski pripravak koji sadrži otopinu metilnaltreksona ili njegove soli i kelatirajući agens, naznačen time da je kelatirajući agens etilendiamintetraoctena kiselina (EDTA) ili njen derivat i gdje otopina ima pH od 3,0 do 3,5.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46161103P | 2003-04-08 | 2003-04-08 | |
PCT/US2004/010997 WO2004091623A1 (en) | 2003-04-08 | 2004-04-08 | Pharmaceutical formulations containing methylnaltrexone |
EP04759349.6A EP1615646B2 (en) | 2003-04-08 | 2004-04-08 | Pharmaceutical formulations containing methylnaltrexone |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20150037T1 HRP20150037T1 (hr) | 2015-06-05 |
HRP20150037T4 true HRP20150037T4 (hr) | 2022-09-02 |
Family
ID=33299842
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150038TT HRP20150038T1 (hr) | 2003-04-08 | 2015-01-12 | Farmaceutske formulacije koje sadrže metilnaltrekson |
HRP20150039TT HRP20150039T1 (hr) | 2003-04-08 | 2015-01-12 | Farmaceutske formulacije koje sadrže metilnaltrekson |
HRP20150037TT HRP20150037T4 (hr) | 2003-04-08 | 2015-01-12 | Farmaceutske formulacije koje sadrže metilnaltrekson |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150038TT HRP20150038T1 (hr) | 2003-04-08 | 2015-01-12 | Farmaceutske formulacije koje sadrže metilnaltrekson |
HRP20150039TT HRP20150039T1 (hr) | 2003-04-08 | 2015-01-12 | Farmaceutske formulacije koje sadrže metilnaltrekson |
Country Status (19)
Country | Link |
---|---|
US (8) | US20040266806A1 (hr) |
EP (3) | EP2368554B1 (hr) |
JP (3) | JP2006522818A (hr) |
CN (2) | CN104383542B (hr) |
AU (2) | AU2004229463B2 (hr) |
BR (1) | BRPI0409133B8 (hr) |
CA (2) | CA2521379C (hr) |
CY (3) | CY1116372T1 (hr) |
DK (3) | DK2368554T3 (hr) |
ES (3) | ES2528631T3 (hr) |
HK (2) | HK1082181A1 (hr) |
HR (3) | HRP20150038T1 (hr) |
IL (1) | IL171228A (hr) |
MX (1) | MXPA05010817A (hr) |
PL (3) | PL2368554T3 (hr) |
PT (3) | PT2368553E (hr) |
RU (1) | RU2362560C2 (hr) |
SI (3) | SI1615646T2 (hr) |
WO (1) | WO2004091623A1 (hr) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
US6274591B1 (en) * | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
WO1999032119A1 (en) | 1997-12-22 | 1999-07-01 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
ATE493130T1 (de) | 2001-05-11 | 2011-01-15 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
EP2243471A1 (en) | 2002-04-05 | 2010-10-27 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
CN104383542B (zh) | 2003-04-08 | 2017-09-26 | 普罗热尼奇制药公司 | 包含甲基纳曲酮的药物配方 |
AU2004229464A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
US20050004155A1 (en) * | 2003-04-08 | 2005-01-06 | Boyd Thomas A. | Use of methylnaltrexone to treat irritable bowel syndrome |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
CN101137378A (zh) * | 2005-01-20 | 2008-03-05 | 普罗热尼奇制药公司 | 甲基纳曲酮和相关化合物治疗术后胃肠功能障碍的用途 |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
MX2007010833A (es) | 2005-03-07 | 2009-02-17 | Univ Chicago | Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales. |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
AR057035A1 (es) * | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
PL1962805T3 (pl) | 2005-12-08 | 2017-01-31 | Insmed Incorporated | Kompozycje środków przeciwzapalnych oparte na lipidach do leczenia infekcji płucnych |
CA2648578A1 (en) * | 2006-04-03 | 2007-11-01 | Nutramax Laboratories, Inc. | Stabilized pentosan polysulfate (pps) formulations and methods of analyzing them |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
TWI489984B (zh) * | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
TW200815451A (en) * | 2006-08-04 | 2008-04-01 | Wyeth Corp | 6-carboxy-normorphinan derivatives, synthesis and uses thereof |
AU2013263750C1 (en) * | 2006-08-04 | 2017-01-12 | Wyeth Llc | Formulations for parenteral delivery of compounds and uses thereof |
TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
WO2008136865A2 (en) * | 2006-11-22 | 2008-11-13 | Progenics Pharmaceuticals, Inc. | (s)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs |
WO2008075997A1 (en) * | 2006-12-21 | 2008-06-26 | Sergey Konstantinovich Sudakov | Method for treating opioid withdrawal syndrome |
US8541459B2 (en) | 2007-01-26 | 2013-09-24 | Pola Pharma Inc. | Pharmaceutical composition |
MX2009010515A (es) | 2007-03-29 | 2009-10-19 | Wyeth Corp | Antagonistas del receptor opioide periferico y usos de los mismos. |
MX2009010552A (es) | 2007-03-29 | 2009-12-14 | Progenics Pharm Inc | Antagonistas de receptor de opioide periferico y usos de los mismos. |
AU2008233133B2 (en) | 2007-03-29 | 2014-03-27 | Progenics Pharmaceuticals, Inc. | Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof |
KR101263225B1 (ko) * | 2007-03-30 | 2013-05-13 | 티오가 파마슈티칼스, 인코포레이티드 | 설사-우세형 및 교대형 과민성 장 증후군의 치료를 위한 카파-아편제 작용제 |
AU2008244936B2 (en) | 2007-04-26 | 2013-02-21 | Toray Industries, Inc. | Stable solid preparation comprising 4,5-epoxymorphinan derivative |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
US8383649B2 (en) | 2007-07-11 | 2013-02-26 | Mallinckrodt Llc | Crystalline forms of naltrexone methobromide |
JP5905198B2 (ja) * | 2007-10-01 | 2016-04-20 | ザ ユニヴァーシティー オヴ シカゴ | 薬剤誘発性吐き気のオピオイド拮抗薬による治療 |
EP2065038A1 (en) * | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
KR101581480B1 (ko) | 2008-02-06 | 2015-12-30 | 프로제닉스 파머슈티컬스, 인코포레이티드 | (r),(r)-2,2'-비스-메틸날트렉손의 제조법 및 용도 |
CA2719134C (en) | 2008-03-21 | 2015-06-30 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
TR201905480T4 (tr) * | 2008-04-18 | 2019-05-21 | Angiochem Inc | Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri. |
EP2306829B1 (en) | 2008-07-01 | 2017-01-04 | University of Chicago | Particles containing a peripheral opioid receptor antagonist |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
CA2740316A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
CN102196811B (zh) | 2008-10-24 | 2014-03-19 | 东丽株式会社 | 含有4,5-环氧基吗啡烷衍生物的稳定片剂 |
BRPI0922689A2 (pt) | 2008-12-05 | 2018-11-06 | Angiochem Inc. | conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos |
DK2405915T3 (en) | 2009-03-10 | 2019-02-11 | Euro Celtique Sa | PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELEASE INCLUDING OXYCODON AND NALOXON |
RU2011146654A (ru) | 2009-04-20 | 2013-05-27 | Ангиокем Инк. | Способы лечения рака яичников с применением конъюгированного средства |
IN2012DN00248A (hr) | 2009-07-02 | 2015-05-01 | Angiochem Inc | |
PT2456424E (pt) * | 2009-07-22 | 2013-09-30 | Gruenenthal Gmbh | Forma de dosagem resistente à adulteração e estabilizada contra a oxidação |
EP3646859A1 (en) | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
MX349145B (es) | 2010-03-11 | 2017-07-14 | Wyeth Llc * | Formulaciones orales y sales lipofilicas de metilnaltrexona. |
ES2642788T3 (es) | 2010-05-10 | 2017-11-20 | Euro-Celtique S.A. | Fabricación de gránulos sin principio activo y de comprimidos que comprenden los mismos |
NZ603170A (en) | 2010-05-10 | 2015-04-24 | Euro Celtique Sa | Combination of active loaded granules with additional actives |
ES2408343B2 (es) | 2010-05-10 | 2014-07-17 | Euro-Celtique, Sa | Composiciones farmacéuticas que comprenden hidromorfona y naloxona |
CA2814805C (en) | 2010-10-21 | 2021-11-02 | Rtu Pharmaceuticals, Llc | Ready to use ketorolac formulations |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
CN102525911B (zh) * | 2012-03-20 | 2013-09-18 | 南京臣功制药股份有限公司 | 一种溴甲纳曲酮注射液及其制备方法 |
RU2483731C1 (ru) * | 2012-04-24 | 2013-06-10 | Федеральное государственное унитарное предприятие "Московский эндокринный завод" | Раствор для инъекций, содержащий налбуфин |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
US10485798B2 (en) | 2012-08-22 | 2019-11-26 | Aptapharma Inc. | Methylnaltrexone nasal formulations, methods of making, and use thereof |
ES2743039T3 (es) * | 2012-11-29 | 2020-02-18 | Insmed Inc | Formulaciones de vancomicina estabilizada |
US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
US9072781B2 (en) * | 2013-03-14 | 2015-07-07 | Becton, Dickinson France S.A.S. | Morphine formulations |
BR112015022171B1 (pt) | 2013-03-14 | 2023-01-03 | Fresenius Kabi Deutschland Gmbh | Sistema de embalagem farmacêutica para um fármaco sensível ao oxigênio injetável |
KR20180037074A (ko) | 2013-07-23 | 2018-04-10 | 유로-셀티큐 에스.에이. | 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물 |
KR102194174B1 (ko) | 2013-11-13 | 2020-12-23 | 유로-셀티큐 에스.에이. | 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손 |
US10238675B2 (en) | 2014-05-15 | 2019-03-26 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
CN104116707B (zh) * | 2014-08-03 | 2016-11-23 | 张星一 | 一种含有溴甲纳曲酮的药物组合物 |
CN104224734A (zh) * | 2014-08-15 | 2014-12-24 | 南京优科生物医药有限公司 | 一种地佐辛冻干粉针剂及其制备方法 |
EP3718404A1 (en) | 2014-10-17 | 2020-10-07 | Salix Pharmaceuticals, Inc. | Use of methylnaltrexone to attenuate tumor progession |
CN105769755A (zh) * | 2014-12-23 | 2016-07-20 | 北大方正集团有限公司 | 一种溴甲纳曲酮注射液及其制备方法 |
CA2989400A1 (en) | 2015-06-15 | 2016-12-22 | Angiochem Inc. | Ang1005 for the treatment of leptomeningeal carcinomatosis |
BR112018072401A2 (pt) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinações de linagliptina e metformina |
CN106176588A (zh) * | 2016-08-09 | 2016-12-07 | 成都佳迪璐莎生物科技有限公司 | 提高盐酸可待因注射制剂稳定性的组合物制备方法 |
CN106265493A (zh) * | 2016-08-09 | 2017-01-04 | 成都佳迪璐莎生物科技有限公司 | 提高盐酸可待因药物注射制剂稳定性的药物组合物 |
EP3558300B1 (en) * | 2016-12-21 | 2021-11-24 | Tioga Pharmaceuticals, Inc. | Solid pharmaceutical formulations of asimadoline |
US20190083386A1 (en) * | 2017-09-15 | 2019-03-21 | Ampersand Biopharmaceuticals, Inc. | Methods and formulations for transdermal administration of buffering agents |
WO2019191627A1 (en) | 2018-03-30 | 2019-10-03 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
WO2020023486A1 (en) | 2018-07-23 | 2020-01-30 | Trevi Therapeutics, Inc. | Treatment of chronic cough, breathlessness and dyspnea |
WO2020033402A1 (en) * | 2018-08-06 | 2020-02-13 | Summit Biosciences Inc. | Drug products for nasal administration and uses thereof |
US11891588B2 (en) | 2019-07-31 | 2024-02-06 | Ecolab Usa Inc. | Personal protective equipment free delimer compositions o |
IT202000002860A1 (it) * | 2020-02-13 | 2021-08-13 | Tred S R L | Composizioni per il trattamento disinfettante della cavità rinofaringea |
Family Cites Families (280)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1420015B1 (de) * | 1959-10-16 | 1971-08-26 | Boehringer Sohn Ingelheim | 2'-Hydroxy-5,9-dimethyl-6,7-benzomorphane |
GB1202148A (en) | 1968-03-06 | 1970-08-12 | Sankyo Co | Pharmaceutical compositions |
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3884916A (en) * | 1971-03-30 | 1975-05-20 | Janssen Pharmaceutica Nv | 2,2-Diaryl-4-(4-aryl-4-hydroxy-piperidino)-butyramides |
US3714159A (en) * | 1971-03-30 | 1973-01-30 | Janssen Pharmaceutica Nv | 2,2-diaryl-4-(4'-aryl-4'-hydroxy-piper-idino)-butyramides |
US4326074A (en) * | 1972-09-22 | 1982-04-20 | William H. Rorer, Inc. | Amidinoureas |
US4025652A (en) | 1975-03-31 | 1977-05-24 | William H. Rorer, Inc. | Amidinoureas |
US3937801A (en) * | 1973-07-10 | 1976-02-10 | American Home Products Corporation | Reducing the incidence of gastrointestinal side effects during the treatment of inflammatory conditions with antiinflammatory drugs |
US4060635A (en) | 1975-03-31 | 1977-11-29 | William H. Rorer, Inc. | Amidinoureas for treating diarrhea |
US4203920A (en) * | 1975-03-31 | 1980-05-20 | William H. Rorer, Inc. | Amidinoureas |
US4066654A (en) * | 1975-04-16 | 1978-01-03 | G. D. Searle & Co. | 1-triarylalkyl-4-phenyl-4-piperidine carboxylic acids and derivatives |
US4072686A (en) * | 1975-04-16 | 1978-02-07 | G. D. Searle & Co. | 1-(3,3,3-Triarylalkyl)-4-phenyl-piperidinealkanols |
US3996214A (en) | 1976-02-23 | 1976-12-07 | G. D. Searle & Co. | 5-(1,1-Diphenyl-4-(cyclic amino) but-2-trans-en-1-yl)-2-alkyl-1,3,4-oxadiazoles and intermediates thereto |
US4013668A (en) * | 1976-03-10 | 1977-03-22 | G. D. Searle & Co. | 5-(1,1-diphenyl-3-(5- or 6-hydroxy-2-azabicyclo(2.2.2)oct-2-yl)propyl)-2-alkyl-1,3,4-oxadiazoles and related compounds |
US4012393A (en) * | 1976-03-22 | 1977-03-15 | G. D. Searle & Co. | 2-[5-(CYCLIC AMINO) ETHYL-10,11-DIHYDRO-5H-dibenzo[a,d]-cyclohepten-5- yl]-5 |
US4115400A (en) | 1976-05-27 | 1978-09-19 | Eli Lilly And Company | 1-Azoniabicyclo[3.1.0]hexanes |
GB1593191A (en) | 1977-03-23 | 1981-07-15 | Reckitt & Colmann Prod Ltd | Derivatives of morphine |
US4125531A (en) | 1977-04-18 | 1978-11-14 | G. D. Searle & Co. | 2-Substituted-1-azabicyclo[2.2.2]octanes |
US4069223A (en) * | 1977-05-02 | 1978-01-17 | G. D. Searle & Co. | 4-Aminomethyl-1-(3,3,3-triarylpropyl)-4-arylpiperidine and derivatives thereof |
US4116963A (en) | 1977-05-23 | 1978-09-26 | G.D. Searle & Co. | 3,3,3-triarylalkyl-4-phenylalkyl-4-hydroxy piperidines and related compounds |
US4194045A (en) * | 1977-12-27 | 1980-03-18 | G. D. Searle & Co. | 1-(3,3-Diaryl-3-oxadiazolalkyl)-4-phenyl-4-piperidinomethanols and related compounds |
IT1096665B (it) | 1978-06-14 | 1985-08-26 | Tecnofarmaci Spa | Composizione farmaceutica per la terapia di stati di frigidita' ed impotenza |
US4176186A (en) | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
JPS5535031A (en) * | 1978-09-04 | 1980-03-11 | Shin Etsu Chem Co Ltd | Enteric coating composition |
US4311833A (en) * | 1979-03-06 | 1982-01-19 | Daicel Chemical Industries Ltd. | Process for preparing ethylcarboxymethylcellulose |
US4277605A (en) | 1980-03-07 | 1981-07-07 | Bristol-Myers Company | Chemical compounds |
US4322426A (en) * | 1980-04-28 | 1982-03-30 | E. I. Du Pont De Nemours And Company | 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4466968A (en) | 1980-11-24 | 1984-08-21 | Dermall, Ltd. | Method for prophylaxis or treatment of emesis and nausea |
US4427676A (en) * | 1980-12-19 | 1984-01-24 | John Wyeth & Brother Ltd. | Thiomorpholine derivatives |
US4377568A (en) * | 1981-08-12 | 1983-03-22 | Merck Sharp & Dohme (I.A.) Corp. | Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same |
DK150008C (da) * | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
DE3381877D1 (de) | 1982-03-16 | 1990-10-18 | Univ Rockefeller | Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen. |
US4987136A (en) * | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
US4870084A (en) | 1982-03-16 | 1989-09-26 | Pfizer Inc. | Bicyclic benzo fused pyran compounds used for nausea treatment and prevention |
US4430327A (en) * | 1982-05-18 | 1984-02-07 | Eli Lilly And Company | Method for treating pregnant females for pain and anxiety |
US4457907A (en) * | 1982-08-05 | 1984-07-03 | Clear Lake Development Group | Composition and method for protecting a therapeutic drug |
US4533739A (en) | 1982-10-12 | 1985-08-06 | G. D. Searle & Co. | 2-[(Aminophenyl and amidophenyl)amino]-1-azacycloalkanes having antidiarrheal activity |
US4518433A (en) * | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US4462839A (en) * | 1983-06-16 | 1984-07-31 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
US4556552A (en) * | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
DE3474511D1 (en) * | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
US4689332A (en) | 1984-04-09 | 1987-08-25 | Research Corporation | Growth regulation and related applications of opioid antagonists |
US5266574A (en) * | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
US4666716A (en) | 1984-09-04 | 1987-05-19 | Richardson-Vicks Inc. | Antidiarrheal compositions and use thereof |
JPS6229515A (ja) * | 1985-07-30 | 1987-02-07 | Shinjiro Tsuji | 硬カプセル剤のフイルムコ−テイング方法 |
JPH0676314B2 (ja) | 1985-09-30 | 1994-09-28 | 花王株式会社 | 坐剤基剤及び坐剤 |
US4824853A (en) * | 1985-10-11 | 1989-04-25 | Janssen Pharmaceutica N.V. | α,α-diaryl-4-aryl-4-hydroxy-1-piperidinebutanamide, N-oxides and method of treating diarrhea |
US4806556A (en) * | 1985-12-12 | 1989-02-21 | Regents Of The University Of Minnesota | Gut-selective opiates |
US4730048A (en) * | 1985-12-12 | 1988-03-08 | Regents Of The University Of Minnesota | Gut-selective opiates |
US4719215A (en) * | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US4861781A (en) | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
DE3609073C2 (de) | 1986-03-18 | 1995-08-10 | Hans J Prof Dr Rer Nat Schmitt | Meßeinrichtung zur nichtinvasiven Feststellung peripherer Abfluß- und Durchflußstörungen in menschlichen Extremitäten |
US4990521A (en) * | 1986-07-03 | 1991-02-05 | Janssen Pharmaceutica | 4-(aroylamino)piperidine-butanimide derivatives |
EP0319545B1 (en) * | 1986-08-28 | 1992-03-18 | Enzacor Properties Limited | Animal growth promotant |
US5597564A (en) * | 1986-08-28 | 1997-01-28 | Enzacor Properties Limited | Method of administering a microgranular preparation to the intestinal region of animals |
US4888346A (en) * | 1986-10-07 | 1989-12-19 | Bernard Bihari | Method for the treatment of persons infected with HTLV-III (AIDS) virus |
US4765978A (en) | 1986-12-16 | 1988-08-23 | Schering Corporation | Novel vaginal suppository |
FR2609632B1 (fr) | 1987-01-21 | 1991-03-29 | Shelly Marc | Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage |
NL8700842A (hr) | 1987-04-10 | 1988-11-01 | Duphar Int Res | |
US4891379A (en) * | 1987-04-16 | 1990-01-02 | Kabushiki Kaisha Kobe Seikosho | Piperidine opioid antagonists |
IL83086A (en) | 1987-07-06 | 1991-03-10 | Teva Pharma | Stable,injectable solutions of vincristine salts |
US4857833A (en) * | 1987-08-27 | 1989-08-15 | Teradyne, Inc. | Diagnosis of faults on circuit board |
CA1315689C (en) | 1987-09-03 | 1993-04-06 | Leon I. Goldberg | Quarternary derivatives of noroxymorphone which relieve nausea and emesis |
ES2051742T3 (es) | 1987-09-10 | 1994-07-01 | Univ Chicago | Derivados cuaternarios de noroxi-morfina que mitigan las nauseas y la emesis. |
US4912114A (en) * | 1988-03-18 | 1990-03-27 | Sandoz Ltd. | Morphinan derivatives |
US5312899A (en) * | 1988-06-30 | 1994-05-17 | Biochem Pharma, Inc. | Dermorphin analogs |
JPH0653683B2 (ja) | 1988-07-14 | 1994-07-20 | ザ ロックフェラー ユニバーシティ | 慢性痛あるいは慢性咳を治療する経口用組成物 |
EP0352361A1 (en) | 1988-07-29 | 1990-01-31 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4999342A (en) * | 1988-08-16 | 1991-03-12 | Ortho Pharmaceutical Corporation | Long lasting contraceptive suppository composition and methods of use |
US4857533A (en) | 1988-12-15 | 1989-08-15 | Baker Cummins Pharmaceuticals, Inc. | Method of treatment for autoimmune diseases |
US4863928A (en) | 1989-01-04 | 1989-09-05 | Baker Cummins Pharmaceuticals, Inc. | Method of treatment for arthritic and inflammatory diseases |
US5102887A (en) | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
US5116868A (en) * | 1989-05-03 | 1992-05-26 | The Johns Hopkins University | Effective ophthalmic irrigation solution |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US4965269A (en) * | 1989-12-20 | 1990-10-23 | Ab Hassle | Therapeutically active chloro substituted benzimidazoles |
US5236947A (en) | 1990-02-28 | 1993-08-17 | Jouveinal S.A. | Propanamines, their pharmacological properties and their application as an antidiarrheal |
JPH0813748B2 (ja) | 1990-04-23 | 1996-02-14 | 帝國製薬株式会社 | 大腸崩壊性ポリペプチド系経口製剤 |
KR970005839B1 (ko) | 1990-05-11 | 1997-04-21 | 화이자 인코포레이티드 | 상승 치료효과를 얻기 위한 조성물 및 방법 |
US5780012A (en) | 1990-06-21 | 1998-07-14 | Huland; Edith | Method for reducing lung afflictions by inhalation of cytokine solutions |
JP3160862B2 (ja) | 1990-11-15 | 2001-04-25 | 雪印乳業株式会社 | 骨強化食品、飼料及び医薬 |
JPH04230625A (ja) * | 1990-12-27 | 1992-08-19 | Standard Chem & Pharmaceut Corp Ltd | 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法 |
DE69231274T2 (de) | 1991-02-25 | 2000-11-30 | Univ Boston | Hyperkinetische bewegungsstörung modulierender opiatrezeptor-antagonist |
JP2916290B2 (ja) | 1991-03-22 | 1999-07-05 | 帝國製薬株式会社 | 生理活性ポリペプチド含有大腸崩壊経口製剤 |
CA2064373C (en) | 1991-03-29 | 2005-08-23 | Buddy Eugene Cantrell | Piperidine derivatives |
US5270328A (en) * | 1991-03-29 | 1993-12-14 | Eli Lilly And Company | Peripherally selective piperidine opioid antagonists |
US5250542A (en) | 1991-03-29 | 1993-10-05 | Eli Lilly And Company | Peripherally selective piperidine carboxylate opioid antagonists |
US5159081A (en) | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
US5220017A (en) | 1991-04-10 | 1993-06-15 | Merck & Co., Inc. | Cholecystokinin antagonists |
WO1993000077A1 (en) * | 1991-06-21 | 1993-01-07 | University Of Cincinnati | Orally administrable therapeutic proteins and method of making |
US5407686A (en) * | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5614219A (en) * | 1991-12-05 | 1997-03-25 | Alfatec-Pharma Gmbh | Oral administration form for peptide pharmaceutical substances, in particular insulin |
US5256154A (en) * | 1992-01-31 | 1993-10-26 | Sterling Winthrop, Inc. | Pre-filled plastic syringes and containers and method of terminal sterilization thereof |
JPH05213763A (ja) | 1992-02-10 | 1993-08-24 | Sanwa Kagaku Kenkyusho Co Ltd | 易吸収活性化カルシウム製剤 |
DE4294862T1 (de) | 1992-04-10 | 1994-06-09 | Vni Skij I Medicinskich Polime | Pharmazeutische Komposition |
US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
USRE36547E (en) * | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
US6096756A (en) * | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5472943A (en) * | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
CA2145985C (en) | 1992-10-28 | 2003-09-16 | Napoleone Ferrara | Vascular endothelial cell growth factor antagonists |
SG52402A1 (en) * | 1992-12-22 | 1998-09-28 | Univ Cincinnati | Oral administration of immunologically active biomolecules and other therapeutic proteins |
DE4303214A1 (de) | 1993-02-04 | 1994-08-11 | Wolfgang Marks | Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone |
US5585348A (en) | 1993-02-10 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia |
US5656290A (en) * | 1993-02-26 | 1997-08-12 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
US5391372A (en) * | 1993-06-28 | 1995-02-21 | Campbell; Elizabeth | Methods of treating colic and founder in horses |
NZ268969A (en) | 1993-07-23 | 1997-06-24 | Toray Industries | Morphinan derivatives and pharmaceutical compositions |
US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
GB2281205A (en) | 1993-08-24 | 1995-03-01 | Euro Celtique Sa | Oral opioid analgesic |
SE9303744D0 (sv) * | 1993-11-12 | 1993-11-12 | Astra Ab | Pharmaceutical emulsion |
US5434171A (en) | 1993-12-08 | 1995-07-18 | Eli Lilly And Company | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
US6190691B1 (en) * | 1994-04-12 | 2001-02-20 | Adolor Corporation | Methods for treating inflammatory conditions |
DE69503126T2 (de) * | 1994-05-05 | 1998-11-12 | Beckman Instruments Inc | Repetitive oligonukleotide matrix |
IT1269826B (it) * | 1994-05-24 | 1997-04-15 | Paolo Minoia | Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate |
US5536507A (en) * | 1994-06-24 | 1996-07-16 | Bristol-Myers Squibb Company | Colonic drug delivery system |
US5866154A (en) * | 1994-10-07 | 1999-02-02 | The Dupont Merck Pharmaceutical Company | Stabilized naloxone formulations |
US5614222A (en) * | 1994-10-25 | 1997-03-25 | Kaplan; Milton R. | Stable aqueous drug suspensions and methods for preparation thereof |
US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US5578725A (en) | 1995-01-30 | 1996-11-26 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
ES2094694B1 (es) * | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. |
US6096763A (en) | 1995-02-23 | 2000-08-01 | Merck & Co., Inc. | α1a adrenergic receptor antagonists |
US6025154A (en) * | 1995-06-06 | 2000-02-15 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein chemokine receptor HDGNR10 |
US5714586A (en) * | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5821219A (en) | 1995-08-11 | 1998-10-13 | Oregon Health Sciences University | Opioid antagonists and methods of their use |
GB9517001D0 (en) | 1995-08-18 | 1995-10-18 | Denny William | Enediyne compounds |
US5804595A (en) * | 1995-12-05 | 1998-09-08 | Regents Of The University Of Minnesota | Kappa opioid receptor agonists |
DK0780372T3 (da) | 1995-12-21 | 2002-03-11 | Syngenta Participations Ag | 3-Amino-2-mercaptobenzoesyrederivater samt fremgangsmåder til deres fremstilling |
KR100469029B1 (ko) | 1996-02-15 | 2005-05-27 | 얀센 파마슈티카 엔.브이. | 세로토닌재흡수억제제의위장효과를극복하기위한5ht4수용체길항제의용도 |
DE69709646T2 (de) | 1996-03-12 | 2002-08-14 | Alza Corp | Zusammensetzung und dosisform mit einem opioid-antagonisten |
US6136780A (en) | 1996-03-29 | 2000-10-24 | The Penn State Research Foundation | Control of cancer growth through the interaction of [Met5 ]-enkephalin and the zeta (ζ) receptor |
US20040024006A1 (en) * | 1996-05-06 | 2004-02-05 | Simon David Lew | Opioid pharmaceutical compositions |
DE19651551C2 (de) | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
US20010036469A1 (en) | 1997-01-13 | 2001-11-01 | Gooberman Lance L. | Opiate antagonist implant and process for preparation therefor |
WO1998035679A1 (de) † | 1997-02-14 | 1998-08-20 | Gödecke Aktiengesellschaft | Stabilisierung von naloxonhydrochlorid |
US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
GB9801231D0 (en) * | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
HU9701081D0 (en) * | 1997-06-23 | 1997-08-28 | Gene Research Lab Inc N | Pharmaceutical composition of antitumoral activity |
US6525038B1 (en) * | 1997-06-24 | 2003-02-25 | Werner Kreutz | Synergistic compositions for the selective control of tumor tissue |
US6353004B1 (en) * | 1997-07-14 | 2002-03-05 | Adolor Coporation | Peripherally acting anti-pruritic opiates |
US6096764A (en) | 1997-08-21 | 2000-08-01 | Eli Lilly And Company | Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration |
US6099853A (en) | 1997-09-04 | 2000-08-08 | Protein Express | Vaginal suppository vaccine for urogenital infections |
US6559158B1 (en) * | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
US5972954A (en) * | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
EP0913152B1 (de) † | 1997-11-03 | 2001-12-19 | Stada Arzneimittel Ag | Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum |
AU2003204844B2 (en) | 1997-11-03 | 2007-06-07 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
US20030158220A1 (en) | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
US6274591B1 (en) * | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
US6777534B1 (en) | 1997-12-09 | 2004-08-17 | Children's Medical Center Corporation | Peptide antagonists of vascular endothelial growth factor |
WO1999032119A1 (en) | 1997-12-22 | 1999-07-01 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
EP0930334A1 (en) | 1998-01-16 | 1999-07-21 | Quest International B.V. | Polysaccharide conjugate capable of binding cellulose |
EP1051493A2 (en) | 1998-01-26 | 2000-11-15 | Unilever Plc | Method for producing antibody fragments |
GB9802251D0 (en) | 1998-02-03 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
PT1068870E (pt) * | 1998-04-03 | 2006-10-31 | Ajinomoto Kk | Agentes antitumorais |
DE19818802A1 (de) | 1998-04-27 | 1999-10-28 | Dresden Arzneimittel | Stabile Mitoxantron-Lösungen |
US6359111B1 (en) * | 1998-05-28 | 2002-03-19 | Neorx Corporation | Opioid receptor targeting |
HN1999000149A (es) * | 1998-09-09 | 2000-01-12 | Pfizer Prod Inc | Derivados de 4,4-biarilpiperidina |
US20010010919A1 (en) | 1998-10-13 | 2001-08-02 | David K. Grandy | Opioid antagonists and methods of their use |
BR9916765A (pt) | 1999-01-05 | 2001-09-25 | Unilever Nv | Processo para produzir um material imunoadsorvente, uso de uma proteìna que é ligada por meio de uma ligação covalente a um fragmento de anticorpo, material imunadsorvente, uso de um material, e, kit de teste diagnóstico |
ATE276359T1 (de) | 1999-01-19 | 2004-10-15 | Unilever Nv | Verfahren zur herstellung von antikörperfragmenten |
CA2293008A1 (en) | 1999-01-28 | 2000-07-28 | Hong Qi | Premixed alatrofloxacin injectable compositions |
WO2000046383A2 (en) | 1999-02-05 | 2000-08-10 | Rijksuniversiteit Leiden | Method of modulating metabolite biosynthesis in recombinant cells |
US6194382B1 (en) * | 1999-03-03 | 2001-02-27 | Albert Einstein College Of Medicine Of Yeshiva University | Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists |
JP4049477B2 (ja) | 1999-03-23 | 2008-02-20 | 大鵬薬品工業株式会社 | 副作用軽減剤 |
WO2000065057A1 (en) | 1999-04-22 | 2000-11-02 | Unilever Plc | Inhibition of viral infection using monovalent antigen-binding proteins |
US7129265B2 (en) | 1999-04-23 | 2006-10-31 | Mason R Preston | Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy |
US6171620B1 (en) | 1999-04-27 | 2001-01-09 | Health Research, Inc. | Method of enhancing the efficacy of anti-tumor agents |
AU4564200A (en) | 1999-04-29 | 2000-11-17 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
US20020068712A1 (en) | 1999-07-23 | 2002-06-06 | Troy Stevens | Use of decreasing levels of functional transient receptor potential gene product |
US20030105121A1 (en) | 1999-07-27 | 2003-06-05 | Bernard Bihari | Method of preventing lipodystrophy syndrome or reversing a pre-existing syndrome in HIV-infected patients being treated with antiretroviral agents |
AU6322900A (en) | 1999-08-02 | 2001-02-19 | Keygene N.V. | Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method |
CA2380524A1 (en) * | 1999-08-25 | 2001-03-01 | Barrett R. Cooper | Compositions and methods for treating opiate intolerance |
ES2226886T3 (es) | 1999-08-31 | 2005-04-01 | Grunenthal Gmbh | Forma de administracion de accion retardada que contiene sacarinato de tramadol. |
US6451806B2 (en) * | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
DE60013630T2 (de) | 1999-11-01 | 2005-09-15 | John Cardiff Rhodes | Arzneimittel zur behandlung von darmverstopfung und reizkolon |
ES2251168T3 (es) * | 1999-11-04 | 2006-04-16 | Institut Gustave Roussy | Agente antiviral en combinacion con radioterapia para el tratamiento del cancer. |
US6384044B1 (en) | 1999-11-29 | 2002-05-07 | Bernard Bihari | Method of treating cancer of the prostate |
US6469030B2 (en) * | 1999-11-29 | 2002-10-22 | Adolor Corporation | Methods for the treatment and prevention of ileus |
DK1244447T3 (da) | 1999-11-29 | 2007-04-23 | Adolor Corp | Nye fremgangsmåder og sammensætninger indeholdende opioider og deres antagonister |
DK1244448T3 (da) | 1999-11-29 | 2009-08-17 | Adolor Corp | Nye metoder til behandling og forebyggelse af ileus |
AU4136901A (en) * | 1999-11-29 | 2001-06-18 | Adolor Corporation | Novel methods for the treatment and prevention of dizziness and pruritus |
US6911455B2 (en) * | 1999-12-22 | 2005-06-28 | Smithkline Beecham Corporation | Methods for preparing pharmaceutical formulations |
US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
US20010046968A1 (en) | 2000-03-23 | 2001-11-29 | Zagon Ian S. | Opioid growth factor modulates angiogenesis |
US6967075B2 (en) * | 2000-04-07 | 2005-11-22 | Schering Corporation | HCV replicase complexes |
WO2001085257A2 (en) | 2000-05-05 | 2001-11-15 | Pain Therapeutics, Inc. | Opioid antagonist compositions and dosage forms |
WO2001097843A2 (en) * | 2000-06-22 | 2001-12-27 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
EP1175905A1 (en) | 2000-07-24 | 2002-01-30 | Societe Des Produits Nestle S.A. | Nutritional Composition |
FI116089B (sv) * | 2000-07-27 | 2005-09-15 | Johan Tore Karlstroem | Anordning och förfaranden vid reglar |
RS50397B (sr) | 2000-07-28 | 2009-12-31 | F. Hoffmann-La Roche Ag., | Farmaceutska smeša |
JP4183371B2 (ja) | 2000-08-31 | 2008-11-19 | 日本・バイオ株式会社 | 発酵ウコンの製造法 |
NZ507152A (en) * | 2000-09-27 | 2001-06-29 | Hiltive Pty Ltd | Wall cladding assembly with cladding having recesses along opposite sides to engage with flanges of support members |
AU2002249885A1 (en) | 2000-11-17 | 2002-08-12 | Adolor Corporation | Delta agonist analgesics |
JP2002229183A (ja) * | 2000-12-01 | 2002-08-14 | Hoya Corp | リソグラフィーマスクブランク及びその製造方法 |
US6967016B2 (en) | 2000-12-04 | 2005-11-22 | Primagen Holding B.V. | Method of determining therapeutic activity and/or possible side-effects of a medicament |
UA73619C2 (en) | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
MXPA03005135A (es) | 2000-12-13 | 2003-12-04 | Lilly Co Eli | Regimen de tratamiento cronico usando peptidos insulinotropicos similares al glucagon. |
KR100405161B1 (ko) | 2000-12-14 | 2003-11-12 | 신풍제약주식회사 | 록소프로펜 함유 근육주사제 조성물 |
GB0100115D0 (en) | 2001-01-04 | 2001-02-14 | Alchemia Pty Ltd | Delivery systems |
US6693125B2 (en) * | 2001-01-24 | 2004-02-17 | Combinatorx Incorporated | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders |
WO2002076472A2 (en) | 2001-03-23 | 2002-10-03 | Shire Biochem Inc. | Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs |
US20040242523A1 (en) | 2003-03-06 | 2004-12-02 | Ana-Farber Cancer Institue And The Univiersity Of Chicago | Chemo-inducible cancer gene therapy |
WO2002080987A1 (en) | 2001-04-09 | 2002-10-17 | Progenics Pharmaceuticals, Inc. | Anti-cd19 immunotoxins |
EP2283845A1 (en) * | 2001-04-26 | 2011-02-16 | pSivida Inc. | Sustained release drug delivery system containing codrugs |
US20030022909A1 (en) * | 2001-06-05 | 2003-01-30 | University Of Chicago | Use of methylnaltrexone to treat immune suppression |
US8012517B2 (en) | 2001-08-31 | 2011-09-06 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Inhibition of angiogenesis and destruction of angiogenic vessels with extracts of noni juice Morinda citrifolia |
EP2939696B1 (en) * | 2001-10-18 | 2016-03-09 | Nektar Therapeutics | Polymer conjugates of opioid antagonists |
US20030144312A1 (en) | 2001-10-30 | 2003-07-31 | Schoenhard Grant L. | Inhibitors of ABC drug transporters in multidrug resistant cancer cells |
WO2003037365A1 (en) * | 2001-11-01 | 2003-05-08 | The Johns Hopkins University | Methods and compositions for treating vascular leak using hepatocyte growth factor |
CA2470519C (en) * | 2001-12-21 | 2009-11-17 | Merck & Co., Inc. | Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
US20050011468A1 (en) * | 2002-02-04 | 2005-01-20 | Jonathan Moss | Use of methylnaltrexone in treating gastrointestinal dysfunction in equines |
US20040259898A1 (en) | 2002-02-04 | 2004-12-23 | Jonathan Moss | Use of methylnaltrexone in treating gastrointestinal dysfunction in equines |
US7074825B2 (en) | 2002-03-07 | 2006-07-11 | Huanbiao Mo | Composition and method for treating cancer |
WO2003077867A2 (en) † | 2002-03-14 | 2003-09-25 | Euro-Celtique, S.A. | Naltrexone hydrochloride compositions |
US20030191147A1 (en) * | 2002-04-09 | 2003-10-09 | Barry Sherman | Opioid antagonist compositions and dosage forms |
US7355081B2 (en) | 2002-04-17 | 2008-04-08 | The University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
US7329642B2 (en) | 2002-05-17 | 2008-02-12 | Board Of Regents, University Of Texas System | β-2-glycoprotein is an inhibitor of angiogenesis |
US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
US6986901B2 (en) * | 2002-07-15 | 2006-01-17 | Warner-Lambert Company Llc | Gastrointestinal compositions |
US20040010997A1 (en) * | 2002-07-17 | 2004-01-22 | Oren Close | Guides to align masonry walls defining apertures, and methods of use |
US7160913B2 (en) * | 2002-09-13 | 2007-01-09 | Thomas Jefferson University | Methods and kit for treating Parkinson's disease |
US7691374B2 (en) * | 2002-10-23 | 2010-04-06 | Health Research, Inc. | Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody |
WO2004043964A2 (en) | 2002-11-08 | 2004-05-27 | Mallinckrodt Inc. | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts |
WO2004054511A2 (en) | 2002-12-13 | 2004-07-01 | The Regents Of The University Of California | Analgesic combination comprising nalbuphine |
WO2004054569A1 (en) * | 2002-12-16 | 2004-07-01 | Council Of Scientific And Industrial Research | Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings |
TW200500067A (en) * | 2003-01-21 | 2005-01-01 | Control Delivery Sys Inc | Salts of codrugs and uses related thereto |
EP1606275B1 (en) | 2003-03-07 | 2008-08-27 | Eli Lilly And Company | Opioid receptor antagonists |
AU2004229464A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
US20050004155A1 (en) * | 2003-04-08 | 2005-01-06 | Boyd Thomas A. | Use of methylnaltrexone to treat irritable bowel syndrome |
CN104383542B (zh) | 2003-04-08 | 2017-09-26 | 普罗热尼奇制药公司 | 包含甲基纳曲酮的药物配方 |
RU2350327C2 (ru) | 2003-04-29 | 2009-03-27 | Ориксиджен Серапьютикс, Инкорпорэйтд | Составы, вызывающие потерю веса |
US6992193B2 (en) | 2003-06-10 | 2006-01-31 | Adolor Corporation | Sulfonylamino phenylacetamide derivatives and methods of their use |
US7494979B2 (en) | 2003-06-13 | 2009-02-24 | Ironwood Pharmaceuticals, Inc. | Method for treating congestive heart failure and other disorders |
DK1644021T3 (da) * | 2003-06-13 | 2012-10-29 | Ironwood Pharmaceuticals Inc | Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme |
AU2003903387A0 (en) | 2003-07-02 | 2003-07-17 | Sirtex Medical Limited | Combination therapy for treatment of neoplasia |
EP1682006A4 (en) * | 2003-10-29 | 2011-01-26 | Physiosonics Inc | METHOD AND DEVICE FOR DETERMINING A MIDDLE LINE OF AN ULTRASONIC LIQUID FLOW |
US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
US8946262B2 (en) | 2003-12-04 | 2015-02-03 | Adolor Corporation | Methods of preventing and treating gastrointestinal dysfunction |
KR20060111581A (ko) | 2003-12-19 | 2006-10-27 | 쉐링 코포레이션 | 약제학적 조성물 |
JP4225922B2 (ja) | 2004-01-15 | 2009-02-18 | アキレス株式会社 | ポリオレフィン系樹脂発泡体シート |
US20070082044A1 (en) * | 2004-03-10 | 2007-04-12 | Trustees Of Tufts College | Synergistic effect of compositions comprising carotenoids selected from lutein, beta-carotene and lycopene |
TW200533339A (en) | 2004-03-16 | 2005-10-16 | Bristol Myers Squibb Co | Therapeutic synergy of anti-cancer compounds |
US6946556B1 (en) | 2004-05-21 | 2005-09-20 | Acura Pharmaceuticals, Inc. | Preparation of opioid analgesics by a one-pot process |
US7094775B2 (en) | 2004-06-30 | 2006-08-22 | Bone Care International, Llc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
US7388008B2 (en) * | 2004-08-02 | 2008-06-17 | Ambrilia Biopharma Inc. | Lysine based compounds |
US20060063792A1 (en) * | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
US20060204512A1 (en) | 2004-09-23 | 2006-09-14 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
WO2006039705A2 (en) | 2004-09-30 | 2006-04-13 | Becton, Dickinson And Company | Method for reducing or eliminating residue in a glass medical container and container made in accordance therewith |
CN101137378A (zh) * | 2005-01-20 | 2008-03-05 | 普罗热尼奇制药公司 | 甲基纳曲酮和相关化合物治疗术后胃肠功能障碍的用途 |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
MX2007010833A (es) | 2005-03-07 | 2009-02-17 | Univ Chicago | Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales. |
AR057035A1 (es) * | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
WO2007053194A2 (en) | 2005-06-03 | 2007-05-10 | The University Of Chicago | Modulation of cell barrier dysfunction |
CA2610951A1 (en) | 2005-06-03 | 2006-12-14 | The University Of Chicago | Modulation of microbial pathogen-host cell interactions |
US20080194611A1 (en) | 2005-06-03 | 2008-08-14 | Alverdy John C | Modulation of Cell Barrier Dysfunction |
MX2007015287A (es) | 2005-06-09 | 2008-02-22 | Mallinckrodt Inc | Metodo para separacion y purificacion de naltrexona por cromatografia de preparacion. |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
CA2627158A1 (en) * | 2005-08-30 | 2007-03-08 | Queen's University At Kingston | Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptoi agonists using an ultralow dose of an alpha-2receptor antagonist |
PL116330U1 (en) | 2005-10-31 | 2007-04-02 | Alza Corp | Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation |
US20070259939A1 (en) | 2006-05-04 | 2007-11-08 | Accelerated Technologies | Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness |
US20080075771A1 (en) * | 2006-07-21 | 2008-03-27 | Vaughn Jason M | Hydrophilic opioid abuse deterrent delivery system using opioid antagonists |
TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
TW200815451A (en) | 2006-08-04 | 2008-04-01 | Wyeth Corp | 6-carboxy-normorphinan derivatives, synthesis and uses thereof |
WO2008021394A2 (en) | 2006-08-15 | 2008-02-21 | Theraquest Biosciences, Llc | Pharmaceutical formulations of cannabinoids and method of use |
TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
CN101678016A (zh) | 2006-11-22 | 2010-03-24 | 普罗基因制药公司 | 4,5-环氧-吗啡烷离子类似物的n-氧化物 |
EP2101774A2 (en) | 2006-11-22 | 2009-09-23 | Progenics Pharmaceuticals, Inc. | 7,8-saturated-4,5-epoxy-morphinanium analogs |
MX2009005463A (es) | 2006-11-22 | 2009-08-28 | Progenics Pharm Inc | Proceso para sintetizar analogos cuaternarios de 4,5-epoxi-morfinano y aislar sus n-estereoisomeros. |
TW200843802A (en) | 2007-02-09 | 2008-11-16 | Drugtech Corp | Compositions for improving gastrointestinal nutrient and drug absorption |
MX2009010552A (es) | 2007-03-29 | 2009-12-14 | Progenics Pharm Inc | Antagonistas de receptor de opioide periferico y usos de los mismos. |
MX2009010515A (es) * | 2007-03-29 | 2009-10-19 | Wyeth Corp | Antagonistas del receptor opioide periferico y usos de los mismos. |
AU2008233133B2 (en) | 2007-03-29 | 2014-03-27 | Progenics Pharmaceuticals, Inc. | Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof |
EA201001643A1 (ru) | 2008-05-07 | 2011-06-30 | Нектар Терапеутикс | Пероральное введение периферически действующих опиоидных антагонистов |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
JP5213763B2 (ja) | 2009-03-03 | 2013-06-19 | キヤノン株式会社 | レンズ鏡筒及びそれを有する光学機器 |
MX349145B (es) | 2010-03-11 | 2017-07-14 | Wyeth Llc * | Formulaciones orales y sales lipofilicas de metilnaltrexona. |
-
2004
- 2004-04-08 CN CN201410683081.XA patent/CN104383542B/zh not_active Expired - Lifetime
- 2004-04-08 MX MXPA05010817A patent/MXPA05010817A/es active IP Right Grant
- 2004-04-08 DK DK10184684.8T patent/DK2368554T3/en active
- 2004-04-08 PT PT10184575T patent/PT2368553E/pt unknown
- 2004-04-08 CA CA2521379A patent/CA2521379C/en not_active Expired - Lifetime
- 2004-04-08 PL PL10184684T patent/PL2368554T3/pl unknown
- 2004-04-08 ES ES10184684.8T patent/ES2528631T3/es not_active Expired - Lifetime
- 2004-04-08 JP JP2006509865A patent/JP2006522818A/ja active Pending
- 2004-04-08 PT PT47593496T patent/PT1615646E/pt unknown
- 2004-04-08 ES ES10184575.8T patent/ES2528669T3/es not_active Expired - Lifetime
- 2004-04-08 SI SI200432215T patent/SI1615646T2/sl unknown
- 2004-04-08 PL PL10184575T patent/PL2368553T3/pl unknown
- 2004-04-08 PL PL04759349.6T patent/PL1615646T5/pl unknown
- 2004-04-08 EP EP10184684.8A patent/EP2368554B1/en not_active Revoked
- 2004-04-08 SI SI200432216T patent/SI2368553T1/sl unknown
- 2004-04-08 EP EP10184575.8A patent/EP2368553B1/en not_active Revoked
- 2004-04-08 CA CA2811272A patent/CA2811272C/en not_active Expired - Lifetime
- 2004-04-08 WO PCT/US2004/010997 patent/WO2004091623A1/en active Application Filing
- 2004-04-08 SI SI200432214T patent/SI2368554T1/sl unknown
- 2004-04-08 US US10/821,811 patent/US20040266806A1/en not_active Abandoned
- 2004-04-08 DK DK04759349.6T patent/DK1615646T4/da active
- 2004-04-08 DK DK10184575.8T patent/DK2368553T3/en active
- 2004-04-08 EP EP04759349.6A patent/EP1615646B2/en not_active Expired - Lifetime
- 2004-04-08 ES ES04759349T patent/ES2527870T5/es not_active Expired - Lifetime
- 2004-04-08 BR BRPI0409133A patent/BRPI0409133B8/pt active IP Right Grant
- 2004-04-08 CN CN200480009192.7A patent/CN1767831B/zh not_active Expired - Lifetime
- 2004-04-08 PT PT101846848T patent/PT2368554E/pt unknown
- 2004-04-08 AU AU2004229463A patent/AU2004229463B2/en not_active Expired
- 2004-04-08 RU RU2005134361/15A patent/RU2362560C2/ru active
-
2005
- 2005-10-02 IL IL171228A patent/IL171228A/en active IP Right Grant
-
2006
- 2006-02-07 HK HK06101582.6A patent/HK1082181A1/xx not_active IP Right Cessation
-
2009
- 2009-12-16 US US12/639,862 patent/US8552025B2/en not_active Expired - Lifetime
- 2009-12-16 US US12/639,880 patent/US20100267758A1/en not_active Abandoned
- 2009-12-16 US US12/639,892 patent/US20100261746A1/en not_active Abandoned
- 2009-12-16 US US12/639,889 patent/US20100261745A1/en not_active Abandoned
-
2010
- 2010-07-05 AU AU2010202824A patent/AU2010202824B2/en not_active Expired
-
2012
- 2012-04-27 JP JP2012103554A patent/JP5847643B2/ja not_active Expired - Lifetime
-
2013
- 2013-09-27 US US14/039,866 patent/US9669096B2/en not_active Expired - Lifetime
-
2015
- 2015-01-12 HR HRP20150038TT patent/HRP20150038T1/hr unknown
- 2015-01-12 HR HRP20150039TT patent/HRP20150039T1/hr unknown
- 2015-01-12 HR HRP20150037TT patent/HRP20150037T4/hr unknown
- 2015-01-28 CY CY20151100091T patent/CY1116372T1/el unknown
- 2015-01-28 CY CY20151100089T patent/CY1116272T1/el unknown
- 2015-01-28 CY CY20151100090T patent/CY1116373T1/el unknown
- 2015-03-24 JP JP2015061493A patent/JP6262169B2/ja not_active Expired - Lifetime
- 2015-09-02 HK HK15108569.7A patent/HK1207965A1/xx unknown
-
2017
- 2017-03-30 US US15/474,614 patent/US10376584B2/en not_active Expired - Lifetime
-
2019
- 2019-06-13 US US16/440,304 patent/US20190358328A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20150037T4 (hr) | Farmaceutske formulacije koje sadrže metilnaltrekson | |
DK1150961T3 (da) | Pyrazolcarboxylsyrederivater, fremstilling af disse og farmaceutiske præparater indeholdende disse | |
HUP0004123A2 (en) | Carboxylic acid amide derivatives, process for their preparation and pharmaceutical compositions containing them | |
HUP0303810A3 (en) | Carboxylic acid derivative and salt thereof and pharmaceutical compositions containing them | |
HUP0301645A3 (en) | Hydropyridine derivative acid addition salts, process for their preparation, pharmaceutical compositions containing them and their use | |
HRP20020880B1 (hr) | Novi farmaceutski pripravak | |
GEP20053510B (en) | Substituted Pyrrolopyridinone Derivatives Useful as Phosphodiesterase Inhibitors | |
DK1095932T3 (da) | Phenoxyeddikesyrederivat og pharmaceutiske sammensætninger omfattende den samme | |
ATE519494T1 (de) | Pharmazeutische zusammensetzungen mit botulinum- toxin | |
GB0012850D0 (en) | Cyclic amino acid derivatives useful as pharmaceutical agents | |
HRPK990402B1 (hr) | Farmaceutski pripravci za primjenu na sluznici | |
HRP20010243B1 (hr) | Pripravci koji sadrže difosfonske kiseline | |
HUP0300896A3 (en) | Beta-amino acid nitrile derivatives, process for their preparation and pharmaceutical compositions containing them | |
PL374325A1 (en) | Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof | |
BR0007294A (pt) | Formulações farmacêuticas aperfeiçoadas | |
NO20035035D0 (no) | Citrasalt av 5,8,14-triazatetracyklo (10.3.1.0 opphöyet 2,11 .0 opphöyet 4,9) - heksadeca-2. (11), 3,5,7,9-pentaen og farmasöytiskesammensetninger derav | |
NO20032371L (no) | Makrolidsolvater | |
DK0871434T4 (da) | Oralt farmaceutisk sammensætning med modificeret frigivelse indeholdende 5-ASA og fremgangsmåde til behandling af tarmsygdomme | |
EP1291362A4 (en) | COMPLEX OF FOLIC ACID AND POLYSACCHARIDES, THE PRODUCTION THEREOF AND THE COMPLEX COMPRISING THE COMPOSITION COMPRISING THE ACTIVE INGREDIENT COMPOSITION | |
NO20031876D0 (no) | Medikamentpreparater på granulatform inneholdende forgrenede aninosyrer ogfremgangsmåter for fremstilling derav | |
HRP20020181B1 (hr) | Farmaceutski pripravci koji sadrže derivat benzamida kao aktivan sastojak | |
HRP20041022B1 (hr) | Injektibilni veterinarski pripravci za male “ivotinje | |
MXPA05008403A (es) | Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion. | |
MY137570A (en) | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease | |
DK1275647T3 (da) | Octahydro-1H-pyrido[1,2-a]pyrazinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse |